Abstracts

202 – Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results

Background Evidence is required to support use of long-acting injectable therapy (LA) in Africa, where demographic factors, viral subtypes, prior treatment, archived drug resistance, and approaches to treatment delivery and monitoring differ from resource-rich settings. We previously reported non-inferior efficacy of LA versus oral antiretroviral therapy (ART) at 48 weeks, but longer-term data are needed…

107 – RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV

Background The extent to which LS-broadly neutralizing antibodies (LS-bNAbs) maintain viral control off ART remains unknown. RIO tested the frequency and durability of viral control of LS-bNAbs compared with placebo in people with treated early HIV.   Methods RIO is a double-blind randomised 1:1 placebo-controlled trial designed to investigate viral control in the absence of ART. Virally-suppressed participants (aged 18-60) who started ART during early HIV received up to two intravenous…

204A – Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1

Background Doravirine (DOR), an NNRTI, and islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor, have complementary mechanisms of action and resistance profiles. MK-8591A-052 is an ongoing phase 3 study evaluating the efficacy and safety of switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) to DOR/ISL (100/0.25 mg), a once-daily single-tablet regimen. Declines in CD4 T-cell and lymphocyte counts…

204B – Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1

Background Doravirine (DOR), a NNRTI, and islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor, have complementary mechanisms of action and resistance profiles. MK-8591A-051 is a phase 3 study evaluating the efficacy and safety of switching from oral ART to DOR/ISL (100/0.25 mg), a once-daily single-tablet regimen. Declines in CD4 and total lymphocyte counts were…

201 – Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox

Background Mpox has caused two international public health emergencies; no therapies have established efficacy. ACTG A5418/STOMP is a phase 3 randomized placebo-controlled double-blind trial evaluating the efficacy of tecovirimat, an antiviral with animal data supporting its use for orthopox infections.  Methods Participants ≥18 years with symptomatic laboratory-confirmed or presumptive mpox <14 days were randomized 2:1…

203 – VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study

Background VH3810109 (N6LS) is a broadly neutralizing CD4-binding site antibody being developed for long-acting HIV-1 therapy. N6LS was well tolerated and efficacious in participants with HIV-1 naive to treatment when administered intravenously (IV) or subcutaneously (SC) in the proof-of-concept phase 2a BANNER study. In the phase 1 SPAN study, single-dose N6LS given IV (60 mg/kg)…

116 – DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy

Background The World Health Organization endorses 3 months of weekly isoniazid and rifapentine (3HP) as TB preventive therapy (TPT) in people with HIV (PWH) on once-daily dolutegravir (DTG)-based antiretroviral treatment (ART). Optimal dosing of DTG to maintain HIV viral suppression in pregnancy while taking 3HP or 1 month of daily isoniazid and rifapentine (1HP) has…